---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-008484"
form_type: "8-K"
ticker: "IMMX"
cik: "0001873835"
company_name: "Immix Biopharma, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:43:56.313999+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Immix Biopharma enters ATM facility to sell up to $5M in common stock

## Summary
- ATM Sales Agreement with ThinkEquity LLC for up to $5,000,000 of common stock.
- Shares sold at market prices; fixed commission of 3.75% of gross proceeds.
- Offering made under existing S-3 shelf registration statement declared effective Jan 2023.
- Expense deposit of $15,000 paid; legal fee reimbursement up to $50,000.

## SEC filing metadata
- accession: 0001493152-23-008484
- form_type: 8-K
- ticker: IMMX
- cik: 0001873835
- company_name: Immix Biopharma, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873835/000149315223008484/0001493152-23-008484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873835/000149315223008484/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-008484
- JSON: https://secwatch.observer/filing/0001493152-23-008484.json
- Plain text: https://secwatch.observer/filing/0001493152-23-008484.txt

## Key facts
- Material Agreements
  Immix Biopharma, Inc. entered into Sales Agreement with ThinkEquity LLC valued at up to $5,000,000 (effective 2023-03-22).
  - Action: entry
  - Agreement: atm program
  - Counterparty: ThinkEquity LLC
  - Value: up to $5,000,000
  - Effective: 2023-03-22
  source text: On March 22, 2023, Immix Biopharma, Inc. (the “Company”) entered into an ATM Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $5,000,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1873835/000149315223008484/0001493152-23-008484-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.